Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses research evaluating repeat exposure to PARP inhibition in patients with platinum-sensitive ovarian cancer.
Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.
Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.
Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.
Manish R. Patel, DO, discusses choosing immunotherapy drugs for patients with non–small cell lung cancer.
Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of rituximab (Rituxan) biosimilars in the treatment of patients with non-Hodgkin lymphoma (NHL).
Elizabeth Petri Henske, MD, director of the Center for LAM Research and Clinical Care, co-director of the Pulmonary Genetics Center at Brigham and Women’s Hospital, and professor at Harvard Medical School, discusses a newly discovered pathway in chromophobe renal cell carcinoma.
Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.
Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).
Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).
Petros Grivas, MD, discusses searching for biomarkers in patients with urothelial cancer to indicate response to pembrolizumab in the KEYNOTE-052 trial.
Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.
Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.
Simon Rule, MD, discusses a study comparing patients with newly diagnosed mantle cell lymphoma who receive immediate systemic treatment immediately versus patients who are closely monitored instead.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.
Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.
Inga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.
Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the evaluation of biosimilars in oncology.
Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses neoadjuvant checkpoint blockade in non–small cell lung cancer (NSCLC).
Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.
Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.
Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the safety profile of lisocabtagene maraleucel (liso-cel; JCAR017) in the TRANSCEND CLL 004 trial.
Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.
Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.
Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.
Steven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.
Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses educational initiatives regarding the use of biosimilars in oncology.
Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab and the PD-1 inhibitor nivolumab, in melanoma.
Toni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.
